...but an obscure Canadian biotech company has just discovered the biggest treatment breakthrough since insulin. This feisty upstart company is poised to capture a HUGE chunk of the $66 billion spent annually on diabetic drugs in the U.S. The company is offering hope to millions - and could hand early investors a whopping 400% return on their money in a matter of months.
Dear Fellow Profit-Seeker:
By the time you hear about it on the evening news, a handful of savvy investors will already be reaping one of the greatest investment windfalls in history:
That's because the small Canadian biotech company I'll tell you about in this special report is about to unveil the most revolutionary treatment for diabetes since the discovery of insulin.
| Canadian biotech's initial target market is 2 million of the most desperate diabetes patients in the U.S. |
TOTAL ESTIMATED VALUE OF CURRENTDIABETES MARKET TO COMPANY: $1.1 BILLION |
In essence, the company may have found a way to increase the effectiveness of this life-giving hormone by up to 20 times - 2,000%!
This is HUGE: For the estimated 40% of diabetes patients for whom insulin alone is not enough... who face serious, potentially fatal complications because they can't get their blood sugar levels under control... any product that can make insulin more effective could be a potential lifesaver.
Best of all, this breakthrough technology is based upon compounds found in ordinary cinnamon. Researchers conducting molecular studies at the U.S. Department of Agriculture, UC Santa Barbara and Iowa State University have discovered that common cinnamon may actually act as an "insulin substitute" in type 2 diabetes - yet it's safe, has no known side effects and works like nothing else on the market.
"Cinnamon itself has insulin-like activity and also can potentiate the activity of insulin," researcher Don Graves of UCSB said. "The latter could be quite important in treating those with type 2 diabetes. Cinnamon has a bio-active component that we believe has the potential to prevent or overcome diabetes."
Amazingly, these insulin-enhancing agents not only normalize blood sugar levels when taken orally, but also appear to remain active for up to two weeks following their discontinuance. That's tremendously important for diabetics, because it's the fluctuations in blood sugar levels that do the most damage to their organs.
And make no mistake: This new product couldn't come at a more crucial time.
According to the World Health Organization, the number of diabetes-related deaths worldwide now exceeds the 3 million people killed each year by HIV/AIDS!
Six times more people die of diabetes worldwide than die of breast, colon, prostate or liver cancer.
In fact, diabetes kills more people than Alzheimer's disease, chronic obstructive pulmonary disease, leukemia, lung cancer, rheumatic or hypertensive heart disease, Parkinson's or MS, tuberculosis, malaria, meningitis or hepatitis, all tropical diseases, leprosy, complications of childbirth, car accidents and war.
You can see why this new treatment has medical researchers waiting eagerly.
And for investors, the profit potential is simply STAGGERING: Last year, the U.S. spent a mind-boggling $132 BILLION - not million - fighting diabetes.
If this tiny Canadian biotech company captures even a tiny percentage of that market, it's going to make early-bird investors as rich as Midas.
The royalties alone for this technology could hit $165 million annually!
The company's superstar diabetes treatment has been featured in mainstream media such as the BBC and Time magazine and industry journals, including the prestigious Diabetes Care.
In a published study of type 2 diabetes patients, the company's cinnamon-derived compounds significantly reduced blood sugar levels by an average of 18-29%, triglycerides (fatty acids in blood) by 23-30%, LDL (or "bad") cholesterol by 7-27% and total cholesterol by 12-26%.
That may not sound like a lot - but to diabetes researchers, this is one of the greatest breakthroughs to come along in decades. The chemical responsible is called methylhydroxy chalcone polymer (MHCP), and laboratory tests found that it boosted glucose processing by up to 20 times!
At the moment, if a diabetic is using an insulin-based treatment system and is temporarily unable to get treatment, it can quickly degenerate into a life-threatening crisis. Without sufficient insulin, glucose accumulates in the blood and urine and the cells of the body are starved - the leading cause of end-stage renal disease, blindness and lower limb amputations.
But once this unknown Canadian company has its product approved and it becomes part of the conventional diabetes treatment regimen used by MILLIONS, going without insulin becomes a far more manageable problem.
Think about what this means!
Imagine a company that has the EXCLUSIVE RIGHT to market a product like insulin. Do you think you could get RICH by buying up shares of a company like this - when they still sell for pennies? You better believe you could!
And that is just what a handful of savvy venture capital dealmakers and entrepreneurs are doing right now.
This Canadian biotech was formed when the founder realized that a major breakthrough in diabetes treatment was unfolding in a U.S. federal laboratory - and the Big Pharma companies were doing NOTHING about it.
In 2004, the entrepreneur's company signed a Cooperative Research and Development Agreement (CRADA) with the United States Department of Agriculture's Agricultural Research Service that extends through 2007.
But it did much more than that. It moved fast and obtained an option to negotiate an exclusive worldwide license to this technology in ALL its applications. In addition, it also gained the right to use state-of-the-art, fully equipped U.S. federal laboratories in the development of this diabetes treatment.
And here's where it gets really exciting: Typically, when a tiny company develops a new drug, patents it and shepherds it through the initial FDA clinical trials, it then licenses the new drug to a Big Pharma company, which then takes over the manufacture and marketing.
Under the resulting arrangement, the tiny firm has negligible overhead and no production costs... but it gets MASSIVE royalties on sales of the drug.
In 2002, U.S. diabetes expenditures were $132 billion. Let's assume that the Canadian biotech's compound will share the market with 20 other compounds that emerge in the next five years.
Further assume that just half the expenditures on diabetes get diverted from crisis care to drug-based prevention and cure.
That translates to an annual diabetes drug market of $66 billion, with the company's licensee realizing one-twentieth of that, or $3.3 billion.
Given that the Canadian company will license its compound at an industry-standard 5% royalty, the company's royalties could quickly hit $165 million.
And get this: These are annual royalties. That's because this company's product, like insulin itself, must be taken for life.
With an industry-standard price-to-earnings ratio of 30, the company could eventually rise from today's market capitalization of just $171 million to be worth an astounding $4.9 billion. That's a potential return of 28 times your money.
But here's the catch: To get in on this deal, you have to act fast.
At the moment, Wall Street institutions don't even know this company exists. Few people do.
But when this product finally receives FDA approval early next year, the big Wall Street funds will begin pouring billions into this obscure Canadian biotech company - and the company's stock will go berserk. At the very least, I fully expect you could triple or even quadruple your money in no time flat.
If you want to know more, send for a free copy of the exhaustive investigative dossier I've just completed on this deal: Mega-Profits in Breakthrough Diabetes Treatments. In it, I tell you exactly when to buy, what price to pay and when to sell.
And that's just the beginning:
This innovative Canadian biotech company is just ONE of SIX unknown tech companies I'm now recommending in my brand-new Emerging Capital Report portfolio.
In this private portfolio of risky, speculative, but potentially blockbuster investments, I reveal six obscure but aggressive tech companies that Wall Street professionals know nothing about - but which have unique technologies that could explode into the headlines almost overnight.
I'll tell you how to get more information on these unknown potential blockbusters in a moment... but first, let me explain why I believe this type of "swing-for-the-bleachers" investing can make sense for a handful of qualified small investors...
| Diabetes now kills more people each year than AIDS... and most other major diseases! |
Because many cases of diabetes can be controlled, the public mistakenly believes that it is a relatively benign disease. But diabetes is anything but benign, and it's quickly becoming a worldwide epidemic:
|
According to the World Health Organization, the number of diabetes-related deaths worldwide now exceeds the 3 million people killed each year by HIV/AIDS! Six times more people die of diabetes worldwide than die of breast, colon, prostate or liver cancer. In fact, diabetes kills more people than Alzheimer's disease, chronic obstructive pulmonary disease, leukemia, lung cancer, rheumatic or hypertensive heart disease, Parkinson's, MS, tuberculosis, malaria, meningitis, hepatitis, all tropical diseases, leprosy, complications of childbirth, car accidents and even (at least recently) war. Would you risk $1,000 on the chance you could turn it into $28,000?
My name is Jonathan Kolber, editor of The Emerging Capital Report.
For more than 20 years, I was an analyst for venture capital companies. It was my job to evaluate new technologies and companies for VC firms that would commit, not a few thousand dollars, but $50 million... $100 million... even $500 million... or more.
Let me tell you: When people put that kind of dough on the line, they expect to see a sizable return on their investment.
And the VC guys do!:
- Michael Moritz of Sequoia Capital and John Doerr of Kleiner Perkins Caufield & Byers invested $25 million to get a relatively unknown company called Google off the ground. For their money, they got 18.6% of the company. Their stake was worth $5.5 billion 5 years later. In other words, these savvy venture capitalists made 220 times their money in 5 years!
- But that's nothing compared with the ROI that Benchmark Capital saw. According to Robert Kagle, one of Benchmark's general partners, its $5 million initial investment in a little Internet company called eBay was worth nearly $4 billion a few years later, a return of 800 times its money!
A few years ago, I decided to stop making billions for fat-cat VC types and start making millions for ordinary investors.
I figured out a way for your average Joes - who would normally not be able to invest in private VC placements - to risk small amounts of money on the chance of making windfall profits.
I was able to do this because of the new way many VC companies now structure company purchases.
Due to the popularity of such sophisticated but little-understood techniques as "reverse mergers," what would have normally been private VC deals are now available to the investing public - but ONLY to those who know what's really going on.
Make no mistake: These are highly risky, speculative ventures that are NOT supposed to be open to the general public. But because of reverse mergers, the shares of the companies (once mere "shells") are traded on public exchanges. Plus, new, strictly enforced disclosure laws require that information once kept top secret must be made available - but again, only if you know where to look for it.
It is 100% legal to invest in these unknown, potentially blockbuster companies, but NO ONE knows about them - least of all the big Wall Street investment and mutual fund companies.
But when you find them, the profits can easily be in the triple digits!
For example, since 2002, I have recommended 47 obscure, high-risk, high-profit-potential tech companies to subscribers to my VIP venture capital advisory, The Emerging Capital Report.
Of the 47 recommendations, 15 have missed the mark... four broke even... and 28 have been potentially profitable.
But look at these gains:
- Nuclear Solutions (NSOL: OTCBB) skyrocketed 1,052% between the time I first recommended it, on Aug. 20, 2004, and April 18 of this year. Every $10,000 flyer subscribers took on this unknown stock could have turned into $105,200
- Cray Inc. (CRAY: NASDAQ), the famous Seattle supercomputer manufacturer, leaped 358% in a year after I first recommended it on May 31, 2005... but after it temporarily fell below $1 in September, it skyrocketed back to $6.93 a share by June 2006 - an additional gain of 593%. If you had invested $10,000 on each of these recommendations, you could have $121,900 sitting in your bank account right now
- PowerChannel (PWRC: Pink Sheets), maker of an Internet access product, showed readers gains of more than 371% in less than 2 months during the winter of 2003-2004
- Semotus Solutions Inc. (DLK: AMEX), software manufacturer for mobile business connection applications, jumped over 244% for readers in just 51 days
- Anatolia Minerals Development Ltd. (ANO: TSE), a mining company that taps underutilized Turkish mineral deposits, yielded readers gains of over 185% from 2002-2004
- One current pick - a nanotech and nuclear tech company with the ability to end terrorist attacks, clean our water and make pinhead-sized batteries - is up an even 400% since my first recommendation
- Other plays include a 141% gain in around 10 months, a 321% gain in 3 months, plus several more solid picks that have yielded an average of 70% in 60 days or less
- Another current Emerging Capital Report portfolio favorite of mine (a small marine propulsion systems innovator) is up 240% and counting in just the last 3 months!
Do you see what I'm talking about? These are the kinds of gains you can achieve when you stop thinking like an "investor" and instead start thinking like a venture capitalist.
They are the kinds of investments that have the potential to make you... not 20% or 50% return on your money... but DOUBLE, TRIPLE, sometimes even QUADRUPLE your money.
Yet as spectacular as the track record of The Emerging Capital Report already is, I'm getting ready to do it again with the brand-new companies I'll introduce you to in my updated 2006-2007 Emerging Capital Report portfolio.
These are stocks you've never heard of - but that are about to turn the technology sector on its ear.
I've introduced you to one of them already.
Here are FIVE more - from my current Emerging Capital Report portfolio...
| For 25-40% of diabetics, insulin won't stop such horrible complications as blindness, heart disease, nerve damage, amputation... and even death! |
| As most people know, diabetes comes in two basic types: Type 1 usually afflicts children and usually means that the pancreas produces no insulin at all. Type 2, the most common type, normally appears in adulthood and means either that the body does not produce sufficient insulin - or does not adequately use the insulin it does produce. Neither type of diabetes has any known cure... and even worse both can develop severe complications that leave patients suffering horribly. Insulin helps to CONTROL blood sugar levels... but it does not always stop the damage that diabetes inflicts on essential organs. The problem with conventional treatments for diabetes - insulin injections... insulin pumps... careful diet... oral medications... and controlled exercise - is that they often fail to offer significant relief from these complications. In a massive, 10-year study by the National Institutes of Health (NIH), scientists discovered that traditional insulin therapy, while controlling blood glucose levels, often does NOT stop the complications of diabetes - including heart, liver, muscle, eye and kidney diseases as well as loss of energy, sleep and sexual function. The scientists concluded that, despite insulin therapy, between 25-40% of all diabetics will develop "overt secondary complications within 10 years." In other words: For tens of millions of people worldwide, traditional insulin treatment doesn't work! In fact, nothing does. All they can look forward to is horrible suffering, blindness - and an early death. But imagine what could happen if a new product boosted the effectiveness of insulin... by 20 TIMES! Can you see why I am so excited about a company that could potentially save the lives of TENS OF MILLIONS of people? Are you beginning to understand why I think this obscure Canadian biotech - totally unknown to Wall Street - could be a HUGE OPPORTUNITY FOR THE TINY HANDFUL OF INVESTORS WHO LEARN ABOUT IT?
|
Emerging Capital Windfall #2:
A Possible 5-Bagger in Memory-Enhancement Products!
Alzheimer's disease and dementia-related conditions are considered the third leading cause of death in the United States, behind cancer and heart disease. And with 75 million baby boomers beginning to retire in 2006, most health experts believe that treatment of memory-related conditions is going to skyrocket over the next 5-10 years.
That's why Alzheimer's and related drug sales were over $1.8 billion in 2005 and are expected to reach $5 billion by 2010.
Regardless of the cause, once the condition has developed, it's generally considered irreversible and very difficult to treat, or even manage. Medications are available, but the side effects are so severe that many people must discontinue use within 6 months. Even worse, they do nothing to arrest the progress of the disease.
But the second company I'll introduce you to in my new Emerging Capital Report portfolio stands to make millions by providing the first real Alzheimer's and memory enhancement breakthrough in years.
The substance behind the company's promising technology is club moss (Huperzia serrata), an ancient Chinese medicine known as Qian Ceng Ta.
In the 20th century, researchers became interested in this ancient Chinese herbal remedy and discovered the active ingredient called huperzine. Scientists in Israel discovered that huperzine appears to neutralize a powerful chemical in the brain, acetylcholinesterase, that destroys nerve and memory cells. Their research indicated that huperzine was effective against several medical conditions, one of them being Alzheimer's disease.
Six U.S. and international patents resulted from this research - also conducted at the Mayo Clinic - and exclusive rights to use them for medical purposes have now been licensed to the second small pharmaceutical company in my Emerging Capital Report portfolio. This includes two "composition of matter" patents and four process patents for huperzine, its analogs and derivatives.
Huperzine has several huge advantages over ALL existing Alzheimer's treatments:
ADVANTAGE #1: Huperzine is more effective in improving cognitive function, and works longer at lower doses than conventional Alzheimer's treatments.
ADVANTAGE #2: Huperzine not only increases the brain's acetylcholine levels, but also boosts levels of other important neurotransmitters, like dopamine and noradrenaline.
ADVANTAGE #3: Unlike other acetylcholine inhibitors, Huperzine actually protects brain cells from further decay.
ADVANTAGE #4: Huperzine offers hope to the 60% of Alzheimer's patients who do not respond to existing medications.
ADVANTAGE #5: Huperzine can be taken for life. With most patients, conventional drugs must be discontinued within six months even though Alzheimer's is a lifelong condition.
ADVANTAGE #6: Huperzine has few, if any, side effects, while all conventional drugs can cause extremely unpleasant side effects, including nausea, vomiting, sweating and even liver toxicity.
ADVANTAGE #7: Huperzine is a smaller molecule with a lower molecular weight than conventional treatments. This makes it uniquely suitable for delivery via the transdermal patch, which eliminates any need to swallow the drug.
In a study of 100 physicians, 97% indicated that they would prefer to prescribe transdermal delivery, as opposed to oral medication. Their reasons include:
- More frequent delivery of the drug, allowing for lower effective dosages
- Less need for caregiver attention
- Greater patient acceptance
- Less chance of forgetting to take medication.
Finally, huperzine is so powerful, and so effective at boosting memory and general cognitive alertness, it also has military and national security significance.
The company has a Cooperative Research and Development Agreement (CRADA) with the U.S. Army. Clinical work has been done at Walter Reed Hospital to determine huperzine's efficacy against nerve gas.
Once the company achieves FDA Phase III clearance, it's quite conceivable the Army will single-source this drug to be taken as a prophylactic by troops who are at risk of being exposed to nerve gas. It could also be stockpiled for homeland security purposes.
BOTTOM LINE: The potential market for this company's product is HUGE - $1.8 billion of competing products were sold last year. This is a proven, established market. As stated above, based on the growth rates in the disease and population demographics, it's predicted to reach $5 billion by 2010.
Assuming the compound passes successfully through FDA Phase III clinical trials next year, the company will either license it to a Big Pharma partner or be acquired outright.
If this company is acquired, it will be at a price at least fivefold higher than the current market capitalization. That's enough to turn every $5,000 invested into $25,000 in the next year or two.
My advice: Learn all you can about this little-known gem while no one knows about it and it's still dirt cheap. I fully expect it to double overnight... and then double again... and then double again.
I'll reveal the name of this potential blockbuster in a new special dossier I've completed, Grow Rich in the Coming Memory Enhancement Bonanza - part of my Emerging Capital Report portfolio. But before I tell you how to find out more about this company, let me tell you about another VC deal I think could make you a small fortune in the coming months...
| 6 reasons why you should consider investing in the Canadian biotech company I've just discovered! |
1. A LIFESAVING TECHNOLOGY: The company's innovative, insulin-enhancing products will permit hundreds of thousands of patients with severe diabetes to live again. Only diabetics can really know what this means. But in concrete terms, this could save the lives of literally thousands of people - and prevent blindness, disfiguring amputations and other horrible complications. 2. A HUGE MARKET: The National Institutes of Health (NIH) study proves that between 25-40% of all diabetics will develop secondary complications of the disease that insulin alone does NOT address. 3. ENORMOUS SAVINGS TO TAXPAYERS: This Canadian company's treatment, if approved, will save the U.S. health care industry and U.S. taxpayers hundreds of billions over the next 10 years. How? Well, with $132 billion spent annually on diabetes treatment - and fully 63% of that for hospitalization due to medical complications - any treatment that can save patients from hospitalizing themselves will save billions. The company's product will cost insurance companies just a few hundred dollars annually, compared with the $100,000 annual average for emergency diabetes hospital stays. 4. GROWING INDUSTRY: Diabetes treatment, unfortunately, will soon be among the world's fastest growing industries. According the World Health Organization, the number of diabetes patients should more than DOUBLE over the next few decades to 340 million people. 5. RECESSION-PROOF BUSINESS: Diabetes has no cure... and patients taking advantage of this Canadian company's products will undoubtedly use them for life. But considering that this company's insulin-boosting compounds could offer enormous improvements in the quality of their lives... AND that Medicare and insurance companies happily pay for the products because of the amount of money they save... this company has a built-in revenue stream that is recession proof. 6. STAGGERING PROFITS: For early investors, this feisty Canadian biotech represents a rare, once-in-a-lifetime opportunity to both do some good... AND reap staggering profits. I believe that early-bird investors could, at the minimum, make 5 TIMES their money on this company... and if sales are as rapid as I believe they will be, there is the potential to make as much as 28 times your money over a decade! |
Emerging Capital Windfall #3:
Mega-Profits in Next-Generation Gene Therapy
The Emerging Capital Report portfolio also includes a small Icelandic company that's about to become a major player in the genetic treatment of disease... it has 32 issued patents and 146 pending patent applications... yet is still unknown to Wall Street.
You've probably heard about Genentech - which pioneered the use of human genetic information to develop and manufacture new drugs.
Genentech's stock jumped 1,000% in just 10 years - skyrocketing from an adjusted price of $6.53 a share in June 1996 to $80 a share a decade later. That's enough to turn every $10,000 invested into $100,000.
But the third company I'll introduce you to in my Emerging Capital Report portfolio could do even better than that.
Founded in 1996, this company already has drugs in the pipeline to prevent and possibly even cure not one, but SEVEN major life-threatening ailments. The ailments include heart attack, arteriosclerosis, stroke, asthma, obesity, type 2 diabetes and schizophrenia.
This unknown company, based in Reykjavik, has figured out how to make customized drugs specific to those genes that cause particular diseases. A whole new level of preventive therapy is becoming possible.
Why Iceland? Well, it's the only country in the world with detailed and complete population records going back more than 11 generations. Without that data, this genetic research would be impossible. That's why this little-known company halfway around the world was awarded a plum $24 million contract by the U.S. National Institutes of Health (NIH).
And it's not just the NIH that's excited about this company and its research. No, it has already forged strategic relationships with some of the world's biggest pharmaceutical companies, including Merck, Roche and Bayer.
Yet because of its isolation in the forbidding and little-understood country of Iceland, Wall Street doesn't even know it exists... even though it already has drugs available that could prevent, and even cure, some of the deadliest diseases now facing mankind:
DRUG #1
May eliminate heart attacks: This company's drug for heart attacks - the leading killer in the industrialized world - has just passed FDA Phase IIa clinical trials. Despite the fact that nearly half of men and one-third of women over 40 will suffer a heart attack, there are no medicines today aimed at directly preventing heart disease.
Until now. This tiny, unknown Icelandic company has discovered the unique gene/protein connection that causes the kind of inflammation that causes most heart attacks - and it's figured out a way to eliminate this risk. The company's drug compound had already been tested for safety by Bayer. And in February 2005, Forbes listed it as one of the most promising experimental drugs
DRUG #2
May eliminate atherosclerosis: Atherosclerosis affects more than 10% of the population, and 1 in 5 people over the age of 70. It's also known as narrowing of the arteries. The body gets starved for oxygen. The current treatment is surgery. No drug is available that targets the underlying causes.
But this Icelandic company has a drug that inhibits the development of atherosclerosis. Animal studies show that it's nontoxic. Enrollment for human clinical testing started in March 2005
DRUG #3
May finally cure asthma: Between 5-20% of people in most European and North American countries have asthma. Air passages in the lungs swell up, making breathing difficult. Many asthma sufferers do not benefit from current medicines, and some experience serious side effects. The company has isolated a gene that triples the risk of asthma. The company is developing a drug that interferes with the gene's expression as inflammation - which will deal with the problem at its source, without side effects
DRUG #4
Could help reduce the number of strokes: Stroke is the third leading cause of death and a leading cause of disability in the industrialized world. Today, there are no medicines to prevent strokes by targeting causes. Yet the company I'll tell you about has discovered an enzyme directly related to stroke risk. It has also identified drugs that should control this enzyme
DRUG #5
Eases the agony of mental illness: Schizophrenia is one of the most devastating illnesses known to man. Onset usually occurs in early adulthood, and it affects its victims for the rest of their lives. The company discovered a gene that makes a protein involved in the part of the brain where neurons communicate. This apparently causes schizophrenia. It's also identified a drug that seems able to restore normal functioning
DRUG #6
Reduces the scourge of adult-onset (type 2) diabetes: Type 2, or adult-onset, diabetes occurs when the body can no longer regulate blood sugar levels. It is associated with high blood pressure and atherosclerosis. It also leads to retinopathy, a disease of the eyes, and neuropathy, degeneration of the nerves, among other things.
The company I'll introduce you to has isolated a gene associated with high risk of developing type 2 diabetes. The gene creates a protein involved in insulin secretion, and appears suitable for medication in a very targeted way. This could lead to a diabetes medicine that keeps the problem under control, or even from developing at all
DRUG #7
May eliminate obesity: Severe obesity is one of the fastest-growing public health challenges in the industrialized world and contributes to many other conditions, from diabetes to heart disease. The company has discovered 3 genes associated with obesity. Based on this insight, it is working with partner company Merck to identify protein targets for the development of new drugs.
Keep in mind that success in bringing to market any one of these seven drugs will put the company squarely on the map as a major pharmaceutical player. Further, by working with giants like Roche, Bayer and Merck - companies with market caps exceeding $25 billion - its chances of success are greatly increased.
By the way, this isn't some raw startup comprised of just a few "propeller heads." No, it's a substantial ongoing concern with a full-time staff of more than 400, 100 of who have Ph.D.s or M.D.s.
The company is currently trading at under $6 a share, after trading at over $10 last year. With a market capitalization of less than $400 million, this company is capable of shaking up the entire pharmaceutical industry, both through specific drug treatments and by changing how clinical research is done throughout the industry.
It carries the usual risks of all biotech companies, but it has a "Magnificent Seven" set of drug candidates in development now - and a total of 50 targeted for future development. Any one of these brought to market successfully as the "gold standard" for treatment should raise the market capitalization of this company into the billions.
Several such hits, and in 5-7 years, we could see this company priced as high as Schering-Plough, currently valued at $28 billion.
I give you all the details on this exciting stock in a special dossier entitled Mega-Profits in Next-Generation Gene Therapy - part of my newly updated Emerging Capital Report portfolio.